Fenclozic Acid

Fenclozic Acid

SCHEMBL27104

O=C(O)Cc1csc(-c2ccc(Cl)cc2)n1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.73
KDM4E B2RXH2 7/20 0.68
ALDH1A1 P00352 4/20 0.68
HPGD P15428 3/20 0.68
GFER P55789 1/20 0.64
GAA P10253 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.59
RAB9A P51151 3/20 0.55
NPC1 O15118 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
TP53 P04637 4/20 0.52
MAPT P10636 1/20 0.52
PTGDR2 Q9Y5Y4 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
SHMT1 P34896 1/20 0.51
SHMT2 P34897 1/20 0.51
RHOC P08134 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12608909 0.86 GFER (0.62) LMNAKDM4EALDH1A1HPGDGFER
SCHEMBL3455040 0.86 GFER (0.62) LMNAKDM4EALDH1A1HPGDGFER
SCHEMBL1422234 0.85 LMNA (0.74) LMNAKDM4EALDH1A1HPGDGAA
SCHEMBL21560039 0.85 SHMT2 (0.72) LMNAKDM4EALDH1A1HPGDGFER
SCHEMBL25410911 0.84 LMNA (0.73) LMNAKDM4EALDH1A1HPGDGAA
SCHEMBL9555508 0.84 LMNA (0.73) LMNAKDM4EALDH1A1HPGDGAA
SCHEMBL9555570 0.84 LMNA (1.00) LMNAKDM4EALDH1A1HPGDGAA
SCHEMBL5461325 0.84 LMNA (0.72) LMNAKDM4EALDH1A1HPGDGAA
SCHEMBL9555459 0.84 KDM4E (0.71) LMNAKDM4EALDH1A1HPGDGAA
SCHEMBL3372557 0.84 LMNA (0.68) LMNAKDM4EALDH1A1HPGDGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 6788 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000741-A1 METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE ACERAGEN INC (US) 2026-01-01 US claimed
EP-4525870-A1 METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT Corcept Therapeutics Incorporated (US) 2025-03-26 EP claimed
EP-4470565-A1 METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT OnQuality Pharmaceuticals China Ltd. (CN) 2024-12-04 EP claimed
CN-118742325-A Methods for preventing or treating diseases or conditions associated with antineoplastic agents 上海岸阔医药科技有限公司 2024-10-01 CN claimed
US-20240245659-A1 Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient CORCEPT THERAPEUTICS INCORPORATED (US) 2024-07-25 US claimed
US-20240041935-A1 PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS CREATIVE MEDICAL TECHNOLOGIES, INC. (US) 2024-02-08 US claimed
US-20230372312-A1 Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient CORCEPT THERAPEUTICS INCORPORATED (US) 2023-11-23 US claimed
WO-2023225282-A1 METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT CORCEPT THERAPEUTICS INCORPORATED (US) 2023-11-23 WO claimed
EP-3752201-B1 SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF UNIV FRIEDRICH ALEXANDER ER (DE) 2023-11-22 EP claimed
WO-2023176987-A1 PREPARATION METHOD FOR BIODEGRADABLE POLYMER FIBRE CHIP 엠엑스바이오 주식회사 2023-09-21 WO claimed
WO-1996012487-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1996012817-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1995031194-A1 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO HOWARD K (US) 1995-11-23 WO claimed
EP-0114886-B1 IMPROVED ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CAFFEINE SUNSHINE, Abraham (US) 1987-09-30 EP claimed
EP-0109036-B1 ANTI-INFLAMMATORY/ANALGESIC COMBINATION OF ALPHA-FLUOROMETHYLHISTIDINE AND A SELECTED NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) MERCK & CO. INC. (US) 1987-09-02 EP claimed
EP-0039051-B1 MANNICH-BASE HYDROXAMIC ACID PRODRUGS FOR THE IMPROVED BIOAVAILABILITY OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS, A PROCESS FOR PREPARING AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM MERCK & CO. INC. (US) 1985-07-24 EP claimed
US-4376767-A ANTIBIOTICS AND PHARMACEUTICALS MERCK & CO., INC. (US) 1983-03-15 US claimed
EP-0055870-A1 Pyridylmethyl esters of selected bio-affecting carboxylic acids, process for preparing and pharmaceutical composition comprising the same MERCK & CO. INC. (US) 1982-07-14 EP claimed
EP-0051278-A1 Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same MERCK & CO. INC. (US) 1982-05-12 EP claimed
EP-0039051-A2 Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them MERCK & CO. INC. (US) 1981-11-04 EP claimed